

Compound A Cell Viability and Target Degradation in OCI-ly10
CTG (% Growth Inhibition)
Degradation (% Control)
Concentration (nM)
Cmpd A IRAK4
Cmpd A Ikaros
Cmpd A CTG
OCI-Ly10
CTG Signal
Time(h)
DMSO
Cmpd A 25nm
Cmpd A 72h wash out
DMSO
CC220 20nM
96h wash out (cc220 treatment)

FIG. 1




Tumor volume (mm3)
2000
1500
1000
500
0
0
5
10
15
20
25
Days after the start of treatment
Vehicle, PO, QDx 28 days
Cmpd B, 10 mg/kg, PO, QD x 28 days
Cmpd A, 3 mg/kg, PO, QD x 28 days
Cmpd A, 10 mg/kg, PO, QD x 28 days
Cmpd A, 30 mg/kg, PO, QD x 28 days

FIG. 2


OCI-Ly10 (Myd88 mut)
Tumor volume (mm3)
2500
2000
1500
1000
500
0
0 5 10 15 20 25 30 35 40
Days after the start of treatment
IV Vehicle (10%HPbCD: 5% TPGS in pH 5-6 water), IV, D1,2,8,9
Compound A, 15 mg/kg, PO, D1, D8, D15
Compound A, 6 mg/kg, IV, D1, D8
Compound A, 12 mg/kg, IV, D1, D8



OCI-Ly10 (Myd88 mut)
Tumor volume (mm3)
2500
2000
1500
1000
500
0
Days after the start of treatment
IV Vehicle (10%HPbCD: 5% TPGS in pH 5-6 water), IV, D1,2,8,9
Compound A, 10 mg/kg, PO, D1,2,8,9
Compound A, 1.5 mg/kg, IV, D1,2,8,9
Compound A, 3 mg/kg, IV, D1,2,8,9
Compound A, 6 mg/kg, IV, D1,2,8,9

FIG. 3



10 MPK single dose
Cmpd A 10mpk Tumor
Cmpd A 10MPK Spleen
Cmpd A 10 mpk Plasma
Tumor IRAK
IKAROS Tumor
Cmpd A Concentration (ng/g)
IRAK4/Ikaros (% of control)
Time (h) post-administrations
0
1000
2000
3000
4000
5000
6000
0
20
40
60
80
100
120
0
24
48
72
96
120

FIG. 4



IV Lymphocytes
Lymphocytes (% Untreated Control)
125
100
75
50
25
0
0
7
14
Vehicle
10 mpk D1
20 MPK D2
5 MPK D1,2
10 MPK D1,2
Exposure Multiples for Efficacy
1.1
2.2
1.7
4.4
PO Lymphocytes
Lymphocytes (% Untreated Control)
125
100
75
50
25
0
0
7
14
Days
Vehicle (M)
50 MPK D1
100 MPK D1 (M)
25 MPK D1,2 (M)
Exposure Multiples for Efficacy
1.2
1.3
1.3

FIG. 5



Intensity
High
QW or BIW
Weekly x2 or x3
4 week cycle
Day: 1 8 15 22
Week 1
Week 2
Week 3
Week 4
Day*: 1 2 8 9 15 16 22 23
Med
QW or BIW
Weekly x2
3 week cycle
Day: 1 8 15
Week 1
Week 2
Week 3
Week 4
Day*: 1 2 8 9 15 16
Low
QW or BIW
Every other week
4 week cycle
Day: 1 15
Week 1
Week 2
Week 3
Week 4
Day*: 1 2 15 16

FIG. 6



Main Study: Assess safety, TK and Blood PD (RAT and NHP)
Schedule 1
BIW | Weekly x2 | 3 week cycle. 3 Dose levels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Schedule 2
BIW | Every other week | 4 week cycle. 2 dose levels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Cmpd A dose
PK, PD, Safety
timepoint
Terminal endpoint
Satellite Groups: assess PD and PK in tissues proximal to dosing (NHP only)
Initiate following first 2 weeks to ensure select tolerable doses
Group 1
1 2 3 4 5
• 3 dose-levels
Group 2
1 2 3 4 5 6 7 8 9 10 11 12

FIG. 7



OCI-Ly10
IC90
16hr
CXCL10
MX1
IFIT3
IFIT1
IRF7
IRAK4
Known IMiD Substrate
Zinc-finger Protein
Interferon Response Protein
-log 10 pvalue
Compound A / DMSO Average
5
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
-2
-1
0
1
2
3
4

FIG. 8



PDX LY14019CD79mut/MYD88L265Pmut
Tumor Volume (mm3)
median
2000
1500
1000
500
0
0
10
20
30
40
Days (post randomization)
Vehicle
Cmpd A, 20 mg/kg PO
D1-3 each week x 3 weeks

FIG. 9



Tumor Volume (mm3)
1600
1400
1200
1000
800
600
400
200
0
0
5
10
15
20
25
Days after the start of treatment
Vehicle
Ibrutinib, 12.5 mg/kg, PO, QD x 21
Cmp A 3 mg/kg, IV, D1,2,15,16
Ibrutinib + Cmp A

FIG. 10




1600
1400
1200
1000
800
600
400
200
0
Tumor Volume (mm3)
0
5
10
15
20
25
Days after the start of treatment
PO Vehicle, PO, QD x 21
Venetoclax, 50 mg/kg, PO, QD x 21
Cmp A 3 mg/kg, IV, D1,2,15,16
Venetoclax + Cmp A

FIG. 11


Tumor Volume (mm3)
3000
2500
2000
1500
1000
500
0
0 10 20 30 40 50 60 70 80 90
Days after the start of treatment
Vehicle
Cmp A, 3 mg/kg, IV, D1,2,8,22,23
Rituxan, 10 mg/kg, IP, BIW
Rituxan + Cmp A



Tumor Volume (mm3)
3000
2000
1000
0
0 10 20 30 40 50 60 70 80 90 100
Days after the start of treatment
Vehicle
RCHOP
Cmp A 3 mg/kg
D72,73 + Rituxan
10mg/kg BIW
R-CHOP
Cmp A + Rituxan
Tumor Volume (mm3)
200
150
100
50
0
70 80 90 100
Days after the start of treatment

FIG. 12